Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches

被引:52
作者
Abdel-Rahman, Emaad M. [1 ]
Saadulla, Lawand [2 ]
Reeves, W. Brian [2 ]
Awad, Alaa S. [2 ]
机构
[1] Univ Virginia, Dept Med, Div Nephrol, Charlottesville, VA USA
[2] Penn State Hershey Med Ctr, Dept Med, Div Nephrol, Coll Med, Hershey, PA USA
关键词
diabetes mellitus; nephropathy; disease management; measurement; therapeutic strategies; ANGIOTENSIN-CONVERTING-ENZYME; BLOOD-PRESSURE CONTROL; URINARY ALBUMIN EXCRETION; CHRONIC KIDNEY-DISEASE; RENIN INHIBITOR ALISKIREN; RANDOMIZED CONTROLLED-TRIAL; GLOMERULAR-FILTRATION-RATE; INTENSIVE GLUCOSE CONTROL; RECEPTOR-GAMMA AGONIST; TISSUE GROWTH-FACTOR;
D O I
10.1007/s11606-011-1912-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Diabetes mellitus is the leading cause of end stage renal disease and is responsible for more than 40% of all cases in the United States. Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, proteinuria/albuminuria reduction, interruption of the renin-angiotensin-aldosterone system through the use of angiotensin converting enzyme inhibitors and angiotensin type-1 receptor blockers, along with dietary modification and cholesterol lowering agents. However, the renal protection provided by these therapeutic modalities is incomplete. More effective approaches are urgently needed. This review highlights the available standard therapeutic approaches to manage progressive diabetic nephropathy, including markers for early diagnosis of diabetic nephropathy. Furthermore, we will discuss emerging strategies such as PPAR-gamma agonists, Endothelin blockers, vitamin D activation and inflammation modulation. Finally, we will summarize the recommendations of these interventions for the primary care practitioner.
引用
收藏
页码:458 / 468
页数:11
相关论文
共 212 条
[1]   Pimagedine: a novel therapy for diabetic nephropathy [J].
Abdel-Rahman, E ;
Bolton, WK .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (04) :565-574
[2]   Diabetic nephropathy: Linking histology, cell biology, and genetics [J].
Adler, S .
KIDNEY INTERNATIONAL, 2004, 66 (05) :2095-2106
[3]   A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy [J].
Agarwal, R ;
Saha, C ;
Battiwala, M ;
Vasavada, N ;
Curley, T ;
Chase, SD ;
Sachs, N ;
Semret, MH .
KIDNEY INTERNATIONAL, 2005, 68 (01) :285-292
[4]   Collecting duct-specific knockout of endothelia-1 causes hypertension and sodium retention [J].
Ahn, D ;
Ge, YQ ;
Stricklett, PK ;
Gill, P ;
Taylor, D ;
Hughes, AK ;
Yanagisawa, M ;
Miller, L ;
Nelson, RD ;
Kohan, DE .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :504-511
[5]   The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus [J].
Ak, G ;
Buyukberber, S ;
Sevinc, A ;
Turk, HM ;
Ates, M ;
Sari, R ;
Savli, H ;
Cigli, A .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2001, 15 (03) :150-157
[6]   Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, Randomized trial [J].
Aljabri, K ;
Kozak, SE ;
Thompson, DA .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 (04) :230-235
[7]  
Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x
[8]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[9]  
[Anonymous], 2007, DIABETES CARE, V30, P4, DOI [DOI 10.2337/DC07-S004, 10.2337/dc07-S004]
[10]  
[Anonymous], 2004, Am J Kidney Dis, V43, pS1